NeuroRapa- Medication for frontotemporal dementia (invented as soon as he learned about Bruce Willis)

Author – Denys Pavlovich Sukhachov

Medication for frontotemporal dementia

Design, Synthesis, and Therapeutic Potential of a Hybrid Rapamycin-Tetrahydrocannabinol (THC) Conjugate for Targeted Therapy

1. Introduction

Rapamycin (sirolimus) and tetrahydrocannabinol (THC) are two bioactive compounds with distinct pharmacological properties:

• Rapamycin: An mTOR inhibitor used as an immunosuppressant and anticancer agent.
• THC: A CB1/CB2 receptor agonist with anti-inflammatory, analgesic, and potential antitumor effects.

Combining these molecules into a hybrid conjugate could enhance therapeutic synergy, reduce toxicity, and improve targeted delivery. This article explores:

• Molecular design (linker selection, modification sites).
• Synthesis strategies (organic chemistry, chemical biology).
• Potential applications (oncology, neurodegenerative diseases).

---

2. Molecular Design of the Conjugate

2.1. Modification Sites

For Rapamycin:

• C40-hydroxyl group – Commonly modified (e.g., in temsirolimus).
• C28-keto group – Can be reduced to OH for conjugation.

For THC:

• Carboxylic acid group (if converted to THC-COOH).
• Hydroxyl group (e.g., 11-OH-THC).

2.2. Linker Selection

The linker must:

• Remain stable in circulation.
• Cleave controllably in target tissues (e.g., tumor microenvironment).

Linker Options:

Linker Type	Example	Pros	Cons
Ester	Rap–O–CO–THC	Simple synthesis	Plasma instability
Disulfide	Rap–S–S–THC	Cleaves under oxidative stress (e.g., in tumors)	Requires SH-modification
Peptide	Rap–GFLG–THC	Tumor protease-specific	Potential immunogenicity
PEG spacer	Rap–PEG4–THC	Improves solubility	May reduce activity

---

3. Synthesis Strategy

3.1. THC Derivative Synthesis

1. THC-COOH preparation:
   1. React THC with succinic anhydride (DMAP catalyst).
   1. Purify via column chromatography.
2. Carboxyl group activation:
   1. Convert to NHS ester (EDC/NHS).

3.2. Rapamycin Modification

1. Introducing a thiol (–SH) group:
   1. Replace C40–OH with –SH via mesylate (MsCl → NaSH).
   1. Alternative: Use heterobifunctional linkers (e.g., SMCC).
2. Conjugation with THC:
   1. Disulfide linker: Oxidize SH groups (H₂O₂ or air).
   1. Peptide linker: Solid-phase synthesis (Fmoc chemistry).

3.3. Purification & Characterization

• HPLC (high-performance liquid chromatography).
• Mass spectrometry (MALDI-TOF).
• NMR (structural confirmation).

---

4. Mechanism of Action & Applications

4.1. Oncology

• Dual targeting of mTOR and endocannabinoid systems:
  • Rapamycin blocks cell proliferation.
  • THC induces apoptosis via CB1/CB2.
• Controlled release: Disulfide linkers cleave in high-ROS tumor environments.

4.2. Neuroprotection

• Alzheimer’s disease:
  • Rapamycin reduces tau aggregation.
  • THC suppresses neuroinflammation via CB2.

4.3. Reduced Toxicity

Conjugation may mitigate rapamycin’s immunosuppressive effects via localized release.

---

5. Challenges & Future Directions

• Bioavailability: Hydrophobicity may require nanoformulations (e.g., lipid nanoparticles).
• Legal considerations: THC use requires regulatory approvals.
• In vivo testing: Animal studies needed for pharmacokinetics.

---

6. Conclusion

The rapamycin-THC conjugate is a promising approach for combination therapy. Optimal linkers (e.g., disulfide or peptide) enable selective release in target tissues. Future work should focus on:

1. Synthesis optimization,
2. Preclinical trials,
3. Delivery systems (nanocarriers).

---

References

1. Nature Reviews Drug Discovery (2023) – mTOR inhibitors.
2. Journal of Medicinal Chemistry (2022) – Hybrid drug design.
3. Patent US20180028577 – Rapamycin conjugates.